Skip to main content

Technologies

11 results found
Pharmaceuticals / Nutraceuticals
Technologies
ID: 2019-015 Recombinant human Gal-1 treatment improves membrane repair capacity, increases myogenic markers and decreases inflammation in dysferlin deficient myotubes, providing novel evidence regarding how Gal-1 favorably improves muscle function in LGMD2B.
Technologies
ID: 2021-010 Using the power of Junctional Adhesion Molecules combined with the target of CAR-T to inhibit cancer metastasis and eradicate tumors.